**Changes in mobility of the golden hamster with induction of an IL-1-induced arthritis**

I. G. Otterness, M. L. Bliven and A. J. Milici

Department of Immunology and Infectious Diseases, Central Research Division, Pfizer Inc., Groton, CT 06340, USA

CA Corresponding Author

**Introduction**

Interleukin-1 (IL-1) has been suggested as an important mediator of arthritic disease. It has been shown *in vitro* to accelerate cartilage proteoglycan loss and to inhibit proteoglycan synthesis. IL-1 is known to be an inducer of other cytokines such as IL-6 and the colony stimulating factors (CSFs), and induces adhesion molecules on endothelial cells and chemotactic cytokines such as IL-8. IL-1 can augment the immune response, and contribute to the formation of granulation tissue and play a role in nonspecific immunity. All these events are part of the inflammatory process.

IL-1 has been shown to produce inflammation and cartilage proteoglycan loss when injected intraarticularly in the rabbit, mouse and rat. Moreover, IL-1 has been shown to have direct involvement in a murine model of arthritis. Previously, it has been shown that systemic administration of IL-1 can lead to decreased locomotor activity in the rat, measured as rearing activity and movement from one quadrant of the cage to another. The possibility was considered that a local arthritis might also affect locomotor activity. However, preliminary studies of activity in locomotor cages showed only minor effects of arthritis on movement, perhaps because of the limited range of movement possible in a 30 x 45 cm cage. A running wheel offered the possibility of extended running activity that could be modified by arthritis. However, the normal untrained rat shows highly variable running. In contrast, a hamster without training will travel many kilometres a night on a wheel or disk and therefore seemed a better species in which to explore the effects of arthritis on mobility. Thus, the consequences of an arthritis induced by local intraarticular administration of IL-1 on mobility of the hamster were studied.

**Methods**

*Animal care and housing:* Female Golden Syrian hamsters (*Mesocricetus auratus*) strain LAK.LVG(SYR) were purchased from Charles River Laboratories (Kingston, NY) at 100–110 g weight. They were maintained on a 10/14 light cycle with food and water *ad libitum* and were acclimated to our facility for at least a week in standard housing before studies were initiated. Hamsters were placed into cages with 33 cm diameter wheels (Nalge, Rochester, NY) at least 3 days prior to manipulation.

*Intraarticular injections:* For intraarticular injection, hamsters were anesthetized with sodium pentobarbitral (80–100 mg/kg i.p.) generally 1–2 h before the dark cycle. The treatment groups were given identical intraarticular injections of 20 µl IL-1α or IL-1β, prepared and characterized as described.
previously, or phosphate buffered saline (PBS) vehicle delivered with a 30-gauge needle into both knees or no injection. The hamsters were weighed, and returned to their cages. Wheel revolutions were continuously recorded. On the day of termination of the experiment, the animals were again anaesthetized, and the left knee was taken for histological analysis.

**Data collection:** Wheels were fitted with magnet reed switches. A 386/25 MHz computer was interfaced with a 24-channel I/O board to collect real-time data. Wheel turns were recorded automatically in 1 min bins and cumulative wheel turns per day recorded. The wheel turns per day for each animal were recorded for 3 to 5 days prior to intraarticular injection and were averaged to determine a normal daily distance (NDD) for each animal. Fractional daily distance for all other days was calculated by dividing the hamster’s distance on that day by the prior NDD. Generally, daily data are presented as the average of the fractional distance of all hamsters in the experimental group ± S.D. For data in which the movement characteristics for individual animals were examined in detail, wheel revolutions were collected in 6 min (0.1 h) intervals. This facilitated analysis on a PC by reducing the analysis of data to 240 points per day.

**Histology:** The hind limbs of control and IL-1 treated animals were removed and fixed overnight in 10% neutral buffered formalin (4°C). Following fixation, the knees were decalcified for 72 h in a 1:1 mixture of 8 N formic acid and 1 N sodium formate (Kristensen’s solution). The knees were then rinsed for 24 h with cold tap water, and routinely processed and embedded in paraplast plus. Great care was used in the mounting of the tissues to ensure that sectioning would begin perpendicular to the medial side of the knee. Sections 3 μm thick were cut from the medial to lateral side of the medial condyle. The sections were numbered and approximately matched sections from all animals were routinely stained with safranin O and fast green and examined using a light microscope.

**Results**

**Normal running pattern:** The hamsters, when placed into a cage with a running wheel, quickly adapted to a consistent running pattern. They generally explore the cage, shortly discovering the wheel. Most are soon carrying out tentative exploration of the wheel motion, and within an hour, most are running as adeptly as seasoned runners. Almost independently of the time of day when they are placed in the cage, they will run greater than 90% of what will become their standard running distance that first night. Except for the exploratory behaviour of the first day, the daily running distance of the normal hamster appears largely constant from day to day over a 10–12 day experimental period, and occurs exclusively during the dark portion of the light cycle.

**Intraarticular IL-1α:** As an initial test to determine whether IL-1 induced inflammation would affect running, we chose to examine an amount of IL-1α (40 ng) that was four times the amount used to give inflammation, inhibition of proteoglycan synthesis and, after three injections, frank proteoglycan loss in the mouse. The amount reflected a compromise between the differences in dose scaling based on surface area (3 x) and body weight (5 x) of a 125 g hamster and a 25 g mouse. Results of a typical experiment are shown in Fig. 1. The normal nightly distance was determined using the 5 days of running prior to the IL-1 injection. After intraarticular IL-1 injection, there is approximately a 40% decrease from the normal daily running distance compared with saline injected controls.

The hamsters were allowed to run for a second night after the primary IL-1 treatment. Running distance was essentially normal. A second injection of IL-1 was then given. As shown in Fig. 1, a much more dramatic inhibition of running was observed after the second exposure to IL-1. In this experiment a mean decrease of 84% from the NDD was found. Surprisingly, even with this much more pronounced suppression of running on night 2, when left to run again on the following night, they ran essentially normal distances.

To examine the relationship between tissue inflammation, cartilage proteoglycan loss, and restoration of mobility, histological sections were taken of the IL-1-injected, the PBS injected, and the control animals after the animals had completed their second night’s run, approximately 40 h following their second intraarticular IL-1 injection.

Histological sections from the PBS injected controls were free from all signs of inflammation. The
Mobility changes with an IL-1 arthritis

soft tissue was free of leukocyte influx (Fig. 2A) and the cartilage proteoglycan staining was normal (Fig. 3A). Sections from the IL-1 treated animals showed clear and unmistakable inflammation of the surrounding soft tissue. There was a heavy leukocyte infiltration into both the deep and superficial soft tissue (Fig. 2B). There was an extensive loss of proteoglycan from the non-calcified layer of the cartilage as demonstrated by loss of safranin O staining, particularly in the pericellular regions which show the most intense staining (Fig. 3B). The synovial fluid continued to show evidence of a mild cellular infiltration and residual fibrin deposits. No comparable changes were observed in either the saline injected or control, non-injected hamsters.

Dose response: The effect of the amount of IL-1 on normal daily distance was examined. IL-1α was given intraarticularly in amounts of 10, 20 and 40 ng. Good inhibition of running by IL-1 was observed at all three doses with a dose responsiveness inhibition of nightly distance (Fig. 4). The ED$_{50}$ is estimated to be about 10 ng/joint. As was observed in the previous experiments, the inhibition of running was much more extensive after the second IL-1 injection when compared with the first injection of IL-1.

Effect of IL-1α vs. IL-1β: Experiments were carried out to determine whether there was a detectable difference in activity between IL-1α and IL-1β, and whether there was any evidence of a synergistic interaction between the two forms of IL-1. In previous experiments, 20 ng of IL-1 intraarticularly gave an intermediate response and therefore, that dose was chosen to be tested. One group received 20 ng of IL-1α, a second group received 20 ng IL-1β, a third

---

**FIG. 2.** Histology of the joint capsule 40 h after the second intraarticular injection saline (a), or 40 ng of IL-1α (b). The tissue sections were stained with safranin O and counterstained with fast green. In Fig. a, the typical appearance of a non-inflamed knee can be seen. There were few cells in the soft connective tissue surrounding the joint (c) and there was no hypertrophy of the synovial lining cells (arrows). In contrast, the effects of the IL-1α injections were clearly visible (Fig. b). There was a perceptible increase in the thickness and cellular content of the soft connective tissue surrounding the joint. In addition, hypertrophy of the synovial lining cells (arrows) was readily apparent. (Magnification = 40 x).

**FIG. 3.** Histology of the articular cartilage 40 h after the second intraarticular injection of saline (a), or of 40 ng of IL-1α (b). The saline injections did not result in any loss of proteoglycan from the articular surface of the femoral condyle (arrowheads) nor as any cell or proteaceous material present in the synovial space, (s). In the IL-1α injected knees, the cartilage proteoglycan was depleted down to the tidemark (arrowheads) and there was an influx of cells and fluid into the joint spaces, (s). (Magnification = 100 x).
I. G. Otterness, M. L. Bliven and A. J. Milici

FIG. 4. Dose responsive inhibition of normal nightly distance after intraarticular injection of IL-1α. Hamsters were allowed to run for 3 nights and a normal nightly distance of 9.3 km/night was found. On the fourth day they were injected with IL-1α, and allowed to run for the following 2 nights. A second intraarticular injection of IL-1 was given and that night’s distance recorded. The mean fractional distance for each group of six hamsters is plotted as a function of the intraarticular IL-1α.

group received 10 ng IL-1α and 10 ng of IL-1β, and a control group received only PBS. The results are given in Fig. 5. No difference was observed between the response to IL-1α and IL-1β, nor was there any evidence of either synergism or antagonism of one form of IL-1 for the other.

Effect of intraperitoneal administration of IL-1α: It has been shown previously that IL-1 given intraperitoneally can inhibit mobility. Therefore the possibility was considered that the effect of intraarticularly administered IL-1 is either purely local, that is, caused by local changes at the site of injection, or might be caused by IL-1α or secondary mediators suffusing from the joint to cause a central inhibition of mobility. The effects of an 80 ng dose of IL-1α administered intraperitoneally (comparable with the highest intraarticular IL-1α dose) were compared with the effects of a 1 μg dose of IL-1α administered intraperitoneally, a dose that had previously been found necessary to inhibit mobility in the rat. The results (Fig. 6) demonstrate that no inhibition of mobility was observed after intraperitoneal administration of the 80 ng dose. However, a modest, but significant, inhibition of mobility was observed when 1 μg of IL-1α was administered intraperitoneally.

Discussion

Modelling changes that take place in mobility during human arthritis by studying the effects of arthritis in animals has not previously been done. Such studies in animals have advantages. Arthritis can be induced acutely and thus changes in mobility parameters can be referred directly back to previously normal values. The effects of different types of arthritis can be explored, and changes in mobility can be related to biochemical, histological and pain parameters studied during the experiment. As an initial test of this hypothesis, intraarticular IL-1 was used as an arthritogen principally because it causes a mild and reversible arthritis and it was speculated that its effects would be primarily local under these circumstances. Thus, some of these conclusions may not be applicable to chronic arthritis where an overlay of systemic disease may change mobility in a fundamental way. Recognizing these qualifications, we still felt that simplicity dictated examination of the consequences of an acute local inflammation on mobility.

FIG. 5. Comparison of the effects of IL-1α and IL-1β on mobility inhibition in the hamster. Four groups of six hamsters were allowed to run for 4 nights and a normal nightly distance calculated for each hamster. The fractional nightly distance is shown for each group of hamsters for the night prior to the first IL-1 injection (night 1), for the night following the first IL-1 injection (night 0) and for the night following the second intraarticular injection (night 2). Four groups of six hamsters were examined. From left to right, the groups are 20 μL PBS, 20 ng IL-1α, 20 ng IL-1β, and 10 ng IL-1α plus 10 ng IL-1β.

FIG. 6. Comparison of 80 ng IL-1α and 1 μg IL-1α given intraperitoneally. Groups of six hamsters were allowed to run for 3 nights, and a normal nightly distance computed for each hamster. On day 3, the IL-1α was administered intraperitoneally and the nightly distance determined.
It was verified that intraarticular IL-1 induced joint inflammation in the hamster. Histologically, as expected from observations in other species, cell infiltration, soft tissue swelling, and proteoglycan loss were observed. The inflammation after a second IL-1 injection was greater than that after the first injection. A single intraarticular saline injection did not prime the joint to a greater response to a subsequent IL-1 injection (data not shown). It is suspected that the enhanced effect of the second IL-1 injection is due to its administration into an already inflamed joint. It has previously been shown that intraarticular IL-1 leads to potentiation of the smoldering arthritis induced with streptococcal cell wall peptidoglycan inducing development of much more extensive pannus, soft tissue swelling and cartilage destruction. Thus, it appears that application of IL-1 to a site already infiltrated by inflammatory cells finds the tissue in a position to respond more readily to IL-1. The second intraarticular injection of IL-1 into a site is also characterized by a greater suppression of daily running distance than the first injection.

When the amount of IL-1 required to obtain an effect on mobility was measured, it was found that a good dose response was obtained in the range of 10–40 ng of IL-1 per joint. This is consistent with the amount of IL-1 which causes histopathological changes and cartilage depletion in mice. Although this amount is well above the levels of IL-1 that can be measured in biological fluids, the rapid distribution and elimination in rodents of murine IL-1α and β, and human IL-1β means that much larger amounts will be required by bolus injection to match that generated by continuous local production. Moreover, as described above, it is likely that the amount of IL-1 required to amplify an existing inflammatory lesion is much less than the amount of IL-1 required to elicit a full blown inflammation de novo. Thus, although it is considered that the amount of IL-1 utilized in these experiments is superphysiological, the changes produced probably reflect those seen following endogenous production.

IL-1α and IL-1β have both been shown to bind equally to the IL-1 type I receptor whereas the type II receptor has been characterized by a preferential binding of IL-1β. The comparable effectiveness of IL-1α and IL-1β in inhibition of mobility implies they are acting at the type I receptor. It has been shown previously by antibody blocking experiments that both IL-1α and IL-1β are involved in inflammation and inhibition of proteoglycan synthesis during arthritis. However, Perretti et al. have reported that peritoneal leukocyte infiltration is predominantly IL-1β dependent, and for effects more distal from the site of inflammation, i.e. weight loss and fever, a selective IL-1β dependency has been found. The possibility that inhibition of mobility could be attributed to systemic rather than local effects was investigated. It has been found previously that continuous administration of IL-1α intraperitoneally in rats leads to inhibition of mobility without local joint pathology. Thus we wondered if the amount of IL-1 given intraarticularly was sufficient to cause systemic inhibition of mobility. A dose of 1 μg of IL-1α injected intraperitoneally inhibited mobility with an effect that was comparable with 20 ng/joint intraarticularly (40 ng total). Sadaro and Dunn using direct intracerebroventricular injection of 77 ng murine IL-1α into mice failed to observe a change in locomotor activity. However, they did observe a reduction in exploratory behaviour to novel stimuli. Dunn et al. reported a decrease in exploratory behaviour at 10 ng i.p. in the rat, but no change in locomotor activity. Thus there is greater inhibition of mobility when IL-1 is given locally rather than systematically.

The nature of the joint inflammation may also affect the outcome of the mobility studies. By using IL-1, a mild inflammatory stimulus was chosen that leads to soft tissue swelling and proteoglycan loss. The articular cartilage is not innervated and it would not be expected to contribute to the loss of mobility. The synovium is, by contrast, known to be innervated and pressure sensitive efferents could transmit a signal suppressing mobility. Surprisingly, in spite of continuing inflammation and soft tissue swelling of the synovium, no impairment of mobility was found the second night after either the first or the second IL-1 injection. This may mean that IL-1 itself, or secondary mediators such as prostaglandins, directly sensitize pain receptors and thus there is impairment of mobility only while the mediators are present. Alternatively, the initial soft tissue swelling may lead to pain, but stress relaxation of the tissue occurs with time (i.e. accommodation of the tissue to distension), and, with stress relaxation, the hyperalgesic response may be lost in the absence of continuing additional inflammatory pressure. Finally, it is also possible that there has been direct evolutionary pressure toward preserving mobility. Hukkanen et al. and Mapp et al. have demonstrated the loss of sensory nerve fibres in inflamed synovium in adjuvant arthritic rats and human rheumatoid arthritic patients, respectively. Mobility compromised by joint inflammation would limit foraging and thus have a negative impact on survival and reproduction. Thus, the rapid restoration of mobility to normal in the presence of continuing inflammation of the joints may be an evolutionary outcome.

References

Mediators of Inflammation · Vol 3 · 1994 · 203